Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

What Was Tested

The trial (not phased) is built around Glatiramer Acetate for multiple sclerosis.

It had two arms (groups): Early Aggressive Therapy (active comparator) and Traditional Therapy (active comparator).

The registry classes the interventions as other.

Who Took Part

900 actual participants took part.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Aged 18-60 years. Must be EITHER John Cunningham (JC) virus antibody negative or low positive (index antibody titer \<0.9), OR negative for: Hepatitis B and C, tuberculosis.

The full record lists 5 inclusion and 8 exclusion criteria; among the exclusions: prior treatment with rituximab, ocrelizumab, ofatumumab, alemtuzumab, mitoxantrone or cladribine; prior treatment with any other ms dmt for more than 6 months; prior treatment with experimental aggressive therapies (e.g., t-cell vaccine, total lymphoid radiation, stem cells).

How the Study Was Run

Design: randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Glatiramer Acetate and who got the comparison, which limits bias.

Groups ran in parallel: each of the multiple sclerosis participants stayed in one arm throughout.

Only one side, usually the multiple sclerosis participants, was kept unaware of whether Glatiramer Acetate was given.

Those kept unaware of assignments: outcomes assessor.

It started in 2018-05-02 with completion listed for 2026-07-31.

It ran at 47 sites in United States (47).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Time to sustained disability progression (time frame: From date of randomization until the date of first documented sustained disability progression, up to 99 months). Change in Overall Burden of MS (time frame: up to 48 weeks from enrollment into COVID-19 related substudy).

It also tracked 26 secondary outcomes, for example Timed 25 Foot Walk Test, Nine-hole Peg Test, Paced Auditory Serial Addition Test (PASAT), Low contrast visual acuity, Neurologic exam-based incomplete relapse recovery and Cognition using Symbol Digit Modality Test (SDMT).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Glatiramer Acetate in 900 people with multiple sclerosis.

With 900 participants it is a large trial for this field.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.